Risperidone and paliperidone induce hyperprolactinemia by blocking dopamine D2 receptors in the pituitary gland, disrupting dopamine’s inhibitory effect on prolactin secretion [13,14]. This evidence concerns the gene DRD2 and hyperprolactinemia.